Lipid-based amphotericin B formulations: from animals to man.

@article{Bekersky1999LipidbasedAB,
  title={Lipid-based amphotericin B formulations: from animals to man.},
  author={Bekersky and Fielding and Buell and Lawrence},
  journal={Pharmaceutical science & technology today},
  year={1999},
  volume={2 6},
  pages={230-236}
}
Amphotericin B has been the mainstay of systemic antifungal therapy for over 30 years, despite its serious side-effects, and, although numerous alternative antifungal agents have been developed, none to date has matched the efficacy of amphotericin B. However, modern drug delivery technology has improved the safety of amphotericin B by incorporating it into lipid-based delivery systems, including liposomes. Three such formulations, based on the natural affinity of amphotericin B for lipids, are… CONTINUE READING